House Publications
The Debates are the report—transcribed, edited, and corrected—of what is said in the House. The Journals are the official record of the decisions and other transactions of the House. The Order Paper and Notice Paper contains the listing of all items that may be brought forward on a particular sitting day, and notices for upcoming items.
For an advanced search, use Publication Search tool.
If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.
| 44th PARLIAMENT, 1st SESSION | |
|
|
|
JournalsNo. 320 Wednesday, May 29, 2024 2:00 p.m. |
|
|
|
|
| Prayer |
| National Anthem |
| Statements By Members |
|
Pursuant to Standing Order 31, members made statements. |
| Oral Questions |
|
Pursuant to Standing Order 30(5), the House proceeded to Oral Questions. |
| Deferred Recorded Divisions |
Government Orders |
|
Pursuant to Standing Order 45, the House resumed consideration of the motion of Mr. Wilkinson (Minister of Energy and Natural Resources), seconded by Mrs. Valdez (Minister of Small Business), — That Bill C-49, An Act to amend the Canada—Newfoundland and Labrador Atlantic Accord Implementation Act and the Canada-Nova Scotia Offshore Petroleum Resources Accord Implementation Act and to make consequential amendments to other Acts, be now read a third time and do pass. |
|
|
The House proceeded to the taking of the deferred recorded division on the amendment of Mr. Bragdon (Tobique—Mactaquac), seconded by Mr. Waugh (Saskatoon—Grasswood), — That the motion be amended by deleting all the words after the word '“That” and substituting the following: |
|
“Bill C-49, An Act to amend the Canada—Newfoundland and Labrador Atlantic Accord Implementation Act and the Canada-Nova Scotia Offshore Petroleum Resources Accord Implementation Act and to make consequential amendments to other Acts, be not now read a third time but be referred back to the Standing Committee on Natural Resources for the purpose of reconsidering Clauses 61, 62, 169, and 170 with the view to prevent uncertainty and a lack of clarity caused by the inclusion of similar provisions contained in Bill C-69, An Act to enact the Impact Assessment Act and the Canadian Energy Regulator Act, to amend the Navigation Protection Act and to make consequential amendments to other Acts, which would insert unanticipated conditions and requirements beyond existing legislation and regulations through these clauses.”.
|
|
|
The question was put on the amendment and it was negatived on the following division: |
|
| (Division No. 787 -- Vote no 787) | |
| YEAS: 116, NAYS: 205 |
|
|
YEAS -- POUR Aboultaif Epp Lewis (Essex) Scheer Total: -- 116 |
|
|
NAYS -- CONTRE Aldag Desbiens Khalid Petitpas Taylor Total: -- 205 |
|
|
PAIRED -- PAIRÉS Bendayan Duncan (Etobicoke North) Gallant Plamondon Total: -- 8 |
|
|
Pursuant to order made Monday, May 27, 2024, under the provisions of Standing Order 78(3), the question was put on the main motion and it was agreed to on the following division: |
|
| (Division No. 788 -- Vote no 788) | |
| YEAS: 176, NAYS: 144 |
|
|
YEAS -- POUR Aldag Dhillon Khalid O'Regan Total: -- 176 |
|
|
NAYS -- CONTRE Aboultaif Dowdall Lemire Savard-Tremblay Total: -- 144 |
|
|
PAIRED -- PAIRÉS Bendayan Duncan (Etobicoke North) Gallant Plamondon Total: -- 8 |
|
|
Accordingly, the bill was read the third time and passed. |
|
Private Members' Business |
|
Pursuant to Standing Order 93(1), the House proceeded to the taking of the deferred recorded division on the motion of Mr. Calkins (Red Deer—Lacombe), seconded by Mr. Vis (Mission—Matsqui—Fraser Canyon), — That Bill C-368, An Act to amend the Food and Drugs Act (natural health products), be now read a second time and referred to the Standing Committee on Health. |
|
|
The question was put on the motion and it was agreed to on the following division: |
|
| (Division No. 789 -- Vote no 789) | |
| YEAS: 171, NAYS: 146 |
|
|
YEAS -- POUR Aboultaif Desjarlais Lantsman Roberts Total: -- 171 |
|
|
NAYS -- CONTRE Aldag Dzerowicz Lamoureux Romanado Total: -- 146 |
|
|
PAIRED -- PAIRÉS Bendayan Duncan (Etobicoke North) Gallant Plamondon Total: -- 8 |
|
|
Accordingly, Bill C-368, An Act to amend the Food and Drugs Act (natural health products), was read the second time and referred to the Standing Committee on Health. |
|
|
|
|
|
Pursuant to Standing Order 93(1), the House proceeded to the taking of the deferred recorded division on the motion of Mr. Poilievre (Carleton), seconded by Ms. Lantsman (Thornhill), — That Bill C-356, An Act respecting payments by Canada and requirements in respect of housing and to amend certain other Acts, be now read a second time and referred to the Standing Committee on Human Resources, Skills and Social Development and the Status of Persons with Disabilities. |
|
|
The question was put on the motion and it was negatived on the following division: |
|
| (Division No. 790 -- Vote no 790) | |
| YEAS: 117, NAYS: 203 |
|
|
YEAS -- POUR Aboultaif Epp Leslie Ruff Total: -- 117 |
|
|
NAYS -- CONTRE Aldag Desbiens Khalid Powlowski Total: -- 203 |
|
|
PAIRED -- PAIRÉS Bendayan Duncan (Etobicoke North) Gallant Plamondon Total: -- 8 |
|
| Motions |
| Daily Routine Of Business |
Tabling of Documents |
|
Pursuant to Standing Order 32(2), Mr. Lamoureux (Parliamentary Secretary to the Leader of the Government in the House of Commons) laid before the House, — Government responses, pursuant to Standing Order 36(8), to the following petitions: |
|
— Nos. 441-02377, 441-02378 and 441-02379 concerning social affairs and equality. |
Presenting Reports from Committees |
|
Mr. Morrissey (Egmont), from the Standing Committee on Human Resources, Skills and Social Development and the Status of Persons with Disabilities, presented the 23rd report of the committee (extension of time, pursuant to Standing Order 97.1, to consider Bill C-322, An Act to develop a national framework to establish a school food program). — Sessional Paper No. 8510-441-449. |
|
A copy of the relevant Minutes of Proceedings (Meeting No. 114) was tabled. |
|
Pursuant to Standing Order 97.1(3), the motion to concur in the report was deemed moved, the question was deemed put and a recorded division was deemed requested and deferred until Wednesday, June 5, 2024, at the expiry of the time provided for Oral Questions. (Concurrence in Committee Reports No. 58) |
Presenting Petitions |
|
Pursuant to Standing Order 36, petitions certified by the Clerk of Petitions were presented as follows: |
|
— by Mr. Shields (Bow River), one concerning government services and administration (No. 441-02489); |
|
— by Mr. Davies (Vancouver Kingsway), one concerning taxation (No. 441-02490) and one concerning employment and labour (No. 441-02491); |
|
— by Mr. Jivani (Durham), one concerning justice (No. 441-02492); |
|
— by Mr. Johns (Courtenay—Alberni), one concerning media and telecommunications (No. 441-02493); |
|
— by Ms. Taylor Roy (Aurora—Oak Ridges—Richmond Hill), one concerning food and drink (No. 441-02494) and one concerning the environment (No. 441-02495); |
|
— by Mr. Morrice (Kitchener Centre), one concerning health (No. 441-02496); |
|
— by Mr. Cooper (St. Albert—Edmonton), one concerning justice (No. 441-02497); |
|
— by Mr. Kurek (Battle River—Crowfoot), one concerning social affairs and equality (No. 441-02498). |
Questions on the Order Paper |
|
Mr. Lamoureux (Parliamentary Secretary to the Leader of the Government in the House of Commons) presented the answers to questions Q-2532, Q-2533, Q-2536, Q-2540 and Q-2544 on the Order Paper. |
|
|
|
Pursuant to Standing Order 39(7), Mr. Lamoureux (Parliamentary Secretary to the Leader of the Government in the House of Commons) presented the revised return to the following question made into an order for return: |
Q-2495 — Mr. Blanchette-Joncas (Rimouski-Neigette—Témiscouata—Les Basques) — With regard to federal spending in the electoral district of Rimouski-Neigette—Témiscouata—Les Basques, broken down by fiscal year since 2018–19, inclusively: (a) what is the total amount for each fiscal year; (b) what is the detailed breakdown of the amounts in (a) by department, Crown corporation, agency or organization; and (c) what grants and contributions were made, broken down by funding source? — Sessional Paper No. 8555-441-2495-01.
|
|
|
|
Pursuant to Standing Order 39(7), Mr. Lamoureux (Parliamentary Secretary to the Leader of the Government in the House of Commons) presented the returns to the following questions made into orders for return: |
Q-2526 — Ms. Duncan (Etobicoke North) — With regard to healthcare in Canada: (a) what is specifically included under universal health services; (b) has the scope of services included under universal health services changed since first implemented and, if so, (i) what are the changes, (ii) on what dates did these changes take place; (c) what are the specific services that are (i) funded publicly, (ii) not fully publicly funded; (d) what was the annual total health spending in Canada, broken down by year from 2010 to present; (e) what was the private total health spending in Canada since 2010 to present; (f) what, if any, publicly insured services are being offered for out-of-pocket pay, and, if relevant, what is the annual spending since 2010; (g) what was the annual per capita spending on health since 2010, and how does per capita spending compare to that of Organisation for Economic Co-operation and Development (OECD) countries; (h) what was the private annual per capita spending on health since 2010; (i) what was the investment in homecare since 2010, and, for each investment, (i) how many more people were served, (ii) what was the average wait time from approval to service delivery, (iii) has the wait time from approval to service delivery changed; (j) what, if any, mechanisms have existed to hold provinces and territories accountable on how they spend the health transfer, and, if relevant, what is (i) the accountability mechanism, (ii) the date; (k) for each province and territory, what is the annual funding compared to the age-adjusted population growth since 2010; (l) for each province and territory, what is specifically included under universal health services; (m) for each province and territory, has the scope of services changed since universal health services were first implemented, and, if so, what are (i) the changes, (ii) the dates of the changes; (n) for each province and territory, what are the specific services that are (i) funded publicly, (ii) not fully publicly funded; (o) for each province and territory, what (i) is the percentage increase in healthcare service costs since the last health transfer, (ii) is the new negotiated health transfer, (iii) new services will the transfer buy for Canadians; (p) where does Canada rank with respect to amenable mortality among comparator countries, and (i) where have there been improvements, (ii) where specifically has there been a lack of improvement; (q) what does Canada spend on pharmaceuticals, and how does Canada rank among the OECD; (r) what are all of the pan-Canadian health benchmarks, and what is the target for each benchmark; (s) for each benchmark, what is the percentage of patients receiving care within each of the pan-Canadian benchmarks, broken down by province and territory; (t) what is the percentage of patients receiving care within the benchmarks for (i) cataract removal, (ii) hip fracture repair, (iii) hip replacement, (iv) knee replacement, broken down by province and territory; (u) how does Canada rank with respect to service wait times for comparator countries, specifically to (i) see a general practitioner, (ii) see a specialist, (iii) be treated in an emergency department, (iv) receive advanced diagnostics, (v) receive elected surgical care; (v) what is the average wait time to (i) see a general practitioner, (ii) see a specialist, (iii) be treated in an emergency department, (iv) receive advanced diagnostics, (v) receive elected surgical care, in each province and territory; (w) how many people left an emergency department in 2022-23 without ever having been seen, broken down by province and territory; (x) what is the health and social services sector vacancy rate in each province and territory; (y) what is the physician supply gap in each province and territory and how does Canada rank against comparator countries; (z) in each province and territory, (i) what is the vacancy rate for nurses, (ii) what discipline has the highest vacancy rate; (aa) broken down by province and territory, what percentage of Canadians lack a primary care provider; (bb) how does Canada rank on inequality in healthcare by income compared to other countries; (cc) what groups of Canadians have difficulty accessing primary care, and, for each group identified, how (i) is access to a general practitioner, (ii) is prescription use, (iii) is access to a specialist, (iv) are diagnostics, (v) is treatment, (vi) is morbidity, (vii) is mortality, impacted; (dd) in each province and territory, what percentage of cost is covered for prescription drugs outside (i) the hospital, (ii) homecare, (iii) non-physician mental health care; (ee) what percentage of income do Canadians in the lowest income quintile spend on their healthcare; (ff) what percentage of income do Canadians in the highest income quintile spend on their healthcare; (gg) broken down by province and territory, (i) how many more people were served with respect to long-term care since 2010 by each federal health transfer, (ii) what was the average wait time from approval to service delivery, (iii) has the wait time from approval to service delivery changed; (hh) broken down by province and territory, what percentage of hospital-bed days is designated to those awaiting long-term care; (ii) how does Canada rank with respect to comparator countries on (i) health outcome measures, (ii) patient-reported experience; (jj) what specific data is collected at the federal level on medical errors, including, but not limited to, (i) patient harm, (ii) a foreign body left in after a procedure, (iii) obstetric trauma, (iv) postoperative pulmonary embolism after a hip replacement, (v) postoperative pulmonary embolism after a knee replacement, and how does this data compare internationally; (kk) what specific data is collected at the provincial and territorial level on (i) medical errors, (ii) patient harm; (ll) how does Canada rank with respect to comparator countries on (i) dental coverage, (ii) non-physician mental health care, (iii) vision? — Sessional Paper No. 8555-441-2526.
|
|
|
Q-2527 — Ms. Duncan (Etobicoke North) — With regard to women’s health in Canada and clinical research funded by the Canadian Institutes of Health Research (CIHR): (a) how much did the government invest in women’s health annually, from 2010 to present, and specifically, for the same time period, how much was invested in (i) aging, (ii) cardiovascular conditions, (iii) neurological conditions, and how did these investments compare to that of the United States; (b) how much did the CIHR invest in women’s health annually, from 2010 to present, and specifically, for the same time period, how much was invested in (i) aging, (ii) cardiovascular conditions, (iii) neurological conditions, and how did these investments compare to that of the National Institutes of Health (NIH); (c) broken down by all common female-specific conditions, including, but not limited to, endometriosis, fibroid tumours, pelvic inflammatory disease, and polycystic ovary syndrome, (i) what are the number of women impacted, (ii) what is the cost to the healthcare system, (iii) what are the effective diagnostics, if any, (iv) what are the effective treatments, if any, (v) is the condition under-researched, (vi) what is the annual investment since 2010, (vii) how does investment compare to that of the United States, (viii) what is the annual investment by CIHR since 2010, (ix) how does investment compare to that of the NIH; (d) what annual investment has the government made since 2010 in (i) fertility, (ii) pregnancy, (iii) maternal health, (iv) reducing maternal morbidity and mortality, (v) breastfeeding, and how does investment compare to that of the United States; (e) what annual investment has the CIHR made since 2010 in (i) fertility, (ii) pregnancy, (iii) maternal health, (iv) reducing maternal morbidity and mortality, (v) breastfeeding, and how does investment compare to that of the NIH; (f) broken down by all specific female cancers including, but not limited to, cervical cancer, ovarian cancer, uterine cancer, vaginal cancer, (i) what is the number of women impacted, (ii) what is the cost to the healthcare system, (iii) what are the effective diagnostics, if any, (iv) what are the effective treatments, if any, (v) what is the average cancer stage at diagnosis, (vi) what is the annual investment by the government since 2010, (vii) how does investment compare to that of the United States, (viii) what is the annual investment by the CIHR since 2010, (ix) how does the investment compare with that of the NIH; (g) broken down by all specific conditions that disproportionately affect women including, but not limited to, autoimmune diseases, chronic pain, Alzheimer’s disease, osteoporosis, and specific cancers, (i) what is the number of women affected, (ii) what is the cost to the health care system, (iii) what is the annual investment by the government since 2010, (iv) how does the investment compare to that of the United States, (v) what is the investment in research by the CIHR annually since 2010, (vi) how does the investment compare to that of the NIH; (h) what percentage of CIHR’s budget is invested in the gender and health institute, and how does this percentage compare to each of the remaining institutes; (i) does CIHR have a policy regarding the sex of animals used in pre-clinical research, and, if so, what are the details of the policy, including the date it came into effect; (j) does all CIHR-supported pre-clinical research require the use of female and male animals; (k) what percentage of CIHR’s pre-clinical research uses female animals, and how is that percentage measured; (l) what percentage of CIHR’s pre-clinical research reports on the sex of animal subjects, and how is it measured; (m) is it mandated that all CIHR-supported clinical research include women, and, if so, what (i) is the date of the mandate, (ii) is the policy, (iii) are the exceptions, (iv) are any requirements for analysis to include sex, gender, and intersectionality, (v) are any requirements for reporting on sex, gender, and intersectionality; (n) how specifically does CIHR track whether clinical research includes women, what are all questions on grant applications, and what questions and formulae are used to calculate the percentage of CIHR-supported clinical research involving women; (o) what percentage of CIHR-supported clinical research involves women; (p) what percentage of CIHR-funded research examines (i) sex, (ii) gender, (iii) intersectionality, and how are these measured; (q) what specific policies has CIHR put in place to ensure women of all ages and backgrounds are included in clinical research populations; (r) does CIHR provide support for research specifically focused on populations of women historically (i) under-represented, (ii) under-researched, (iii) under-reported, in clinical research, and, if so, what specific investment is made for each? — Sessional Paper No. 8555-441-2527.
|
|
|
Q-2528 — Mr. Bezan (Selkirk—Interlake—Eastman) — With regard to the Defence Policy Update and the statement that “The government is projecting our defence spending to GDP ratio to reach 1.76% in 2029-30”: (a) what is the projected defence budget broken down by fiscal year from 2023-24 to 2029-30; (b) how much of that is allocated from the Defence Policy Update as a dollar value; (c) what is the projected GDP, broken down by fiscal year from 2023-24 to 2029-30; and (d) what is the projected defence spending to GDP ratio broken down by fiscal year from 2023-24 to 2029-30? — Sessional Paper No. 8555-441-2528.
|
|
|
Q-2529 — Mr. Lobb (Huron—Bruce) — With regard to government advertising during or connected to the Super Bowl, including the pre- and post-game broadcasts, on February 11, 2024: (a) what was the total amount spent on advertising; and (b) what is the breakdown of the spending by each advertisement, including a description of the contents, and by media outlet, along with when the advertisement ran (pre-game, during the game, etc.)? — Sessional Paper No. 8555-441-2529.
|
|
|
Q-2530 — Mr. Lobb (Huron—Bruce) — With regard to government grant programs which are or have been administered by external parties or vendors since 2016: what are the details of all such programs, including, for each, the (i) name of the program, (ii) description or purpose of the program, (iii) amount of funding provided through the grants, (iv) number of grant recipients, (v) name of the external party or vendor that administered the program, (vi) amount paid to the external party or vendor for administering the program, (vii) reason the government outsourced the administration of the program? — Sessional Paper No. 8555-441-2530.
|
|
|
Q-2531 — Mr. Jivani (Durham) — With regard to the Housing Accelerator Fund: (a) what is the total amount of funding allocated in Ontario, broken down by each municipality; and (b) what is the breakdown of (a), by type of housing funded? — Sessional Paper No. 8555-441-2531.
|
|
|
Q-2534 — Mr. Redekopp (Saskatoon West) — With regard to Immigration, Refugees and Citizenship Canada (IRCC) and the Settlement Program, the Resettlement Assistance Program, the Interim Housing Assistance Program, the International Migration Capacity Building Program, and the Francophone Immigration Support Program, for the fiscal years 2015-16 to 2023-24, broken down by program and by province and territory: (a) what organizations applied for grants, contributions or loans; (b) how much did they apply for on an annual basis; (c) how much did they receive on an annual basis; (d) how much of their funding did IRCC allocate to administrative costs on an annual basis; and (e) what were the actual administrative costs on an annual basis? — Sessional Paper No. 8555-441-2534.
|
|
|
Q-2535 — Mr. Barlow (Foothills) — With regard to the government’s online estimators: (a) what were the costs associated with developing and implementing the AgriStability estimator, in total and broken down by type of expense; (b) what are the details of all contracts signed by the government related to (a), including, for each, the (i) date, (ii) vendor, (iii) value, (iv) description of goods or services; (c) what were the costs associated with developing and implementing the Canada Carbon Rebate estimator, in total and broken down by type of expense; and (d) what are the details of all contracts signed by the government related to (c), including, for each, the (i) date, (ii) vendor, (iii) value, (iv) description of goods or services? — Sessional Paper No. 8555-441-2535.
|
|
|
Q-2537 — Mrs. Vecchio (Elgin—Middlesex—London) — With regard to the revocation of government security clearances between January 1, 2023, and April 11, 2024: (a) how many individuals have had their security clearances revoked for cause (and not as a result of retirement or resignation); (b) of the revocations in (a), how many were due to the individual spying or otherwise acting on behalf of a foreign government; and (c) what is the breakdown of (a) and (b) by department, agency, Crown corporation, or other government entity? — Sessional Paper No. 8555-441-2537.
|
|
|
Q-2538 — Mrs. Vecchio (Elgin—Middlesex—London) — With regard to the revocation of government security clearances for ministerial exempt staff, including those from the Office of the Prime Minister, between January 1, 2016, and April 11, 2024: (a) how many individuals have had their security clearances revoked for cause (and not as a result of retirement or resignation); and (b) what is the breakdown of (a) by (i) year, (ii) minister whom they were working for at the time of revocation, (iii) reason for revocation? — Sessional Paper No. 8555-441-2538.
|
|
|
Q-2539 — Mr. Soroka (Yellowhead) — With regard to the Public Health Agency of Canada's procurement of ventilators from Canadian Emergency Ventilators Inc. in April 2020, and the subsequent sale of many of these ventilators as commodity code "9500 - Scrap metal" through the GC Surplus auction: (a) why were the ventilators classified and sold as scrap metal; (b) did the government offer these ventilators to the (i) provincial health authorities, (ii) National Emergency Strategic Stockpile, (iii) Department of National Defence, (iv) International Development section of Global Affairs Canada; (c) for each entity in (b) that received an offer, what reason was received by the government for the entity not accepting the ventilators; (d) for each entity in (b) that did not receive an offer, why did the government not offer the ventilators to them; (e) for the ventilators that have been disposed of to date, through either GC Surplus or other means, who was the recipient of the ventilators, what quantity did each recipient receive, and how much payment did the government receive; (f) have any of these ventilators ended up in private or for-profit health care entities, either in Canada or abroad, and, if so, what are the details; and (g) if the government does not know the answer to (f), why does the government not have that information? — Sessional Paper No. 8555-441-2539.
|
|
|
Q-2541 — Mr. Albas (Central Okanagan—Similkameen—Nicola) — With regard to the granting of government security clearances between January 1, 2023, and April 1, 2024: (a) how many individuals (i) applied for, (ii) were denied (not as a result of retirement or resignation), security clearances; (b) of the denials in (a), how many were due to the individual spying or otherwise acting on behalf of a foreign government; and (c) what is the breakdown of (a) and (b) by department, agency, Crown corporation, or other government entity and level of clearance applied (secret or top secret)? — Sessional Paper No. 8555-441-2541.
|
|
|
Q-2542 — Mrs. Gray (Kelowna—Lake Country) — With regard to the Canada Digital Adoption Program: (a) how many of the 29,532 businesses which applied to the Boost Your Business Technology Stream were successful and received funding; (b) what was the total amount of funding given to businesses through the Boost Your Business Technology Stream; (c) what is the breakdown of the $13 million provided in the contribution agreement with Magnet for project implementation and administrative costs; (d) what are the details of third-party contractors who received money from the $13 million, including, for each, (i) their name, (ii) the amount received, (iii) the goods or services provided; (e) what are the names of all third-party contractors who received funding through this project implementation and administrative cost stream; (f) what were the amounts paid to each third-party contractor who received funding through this project implementation and administrative cost stream; (g) what were the work descriptions of each third-party contractor who received funding through this project implementation and administrative cost stream; (h) what is the breakdown by school of the 1,954 students who were hired as of December 31, 2023, as E-commerce Advisors; (i) what is the breakdown of the advertising used to advertise these positions; (j) what were the work descriptions of these positions; (k) what is the breakdown by school of the 1,255 youth who were hired to support participating Canadian small and medium enterprises in the implementation of their digital adoption plans; (l) what is the breakdown of the advertising used to advertise these positions; (m) what were the work descriptions of these positions; (n) how many E-commerce Advisors and youths who were hired to support businesses with the implementation of their digital adoption plans were the same person; and (o) what is the breakdown by school of these individuals? — Sessional Paper No. 8555-441-2542.
|
|
|
Q-2543 — Mrs. Gray (Kelowna—Lake Country) — With regard to travel expenses related to the Benefits Delivery Modernization Programme, since January 1, 2017: (a) what is the total number of travel expenses filed; (b) what is the total cost of travel expenses filed; (c) what is the cost of travel expenses filed by public servants; (d) what is the cost of travel expenses filed by third-party contractors; (e) what is the cost of flights expensed by public servants; (f) what is the cost of lodgings expensed by public servants; (g) what is the cost of per diems expensed by public servants; (h) what is the cost of flights expensed by third-party contractors; (i) what is the cost of lodgings expensed by third-party contractors; (j) what is the cost of per diems expensed by third-party contractors; and (k) what is the breakdown of (a) to (j) by month and by quarter? — Sessional Paper No. 8555-441-2543.
|
|
|
Q-2545 — Ms. Duncan (Etobicoke North) — With regard to cancer in Canada: (a) what are the top 10 cancers annually since 2010, broken down by province and territory, and, for each cancer, what is the (i) morbidity rate, (ii) mortality rate, (iii) five-year net survival rate; (b) how do the rates in (a)(i), (a)(ii), (a)(iii) compare to the United States; (c) for the rates in (a)(i) and (a)(ii), what is the (i) number of people affected, (ii) cost to the health care system, (iii) total investment compared to the United States; (d) are there any types of cancer on the rise in Canada, and, if so, what are they, broken down by province and territory; (e) what percentage of new patients are offered a diagnostic molecular test in Canada; (f) what percentage of patients are offered a clinical trial in Canada; (g) what percentage of patients are enrolled in a clinical trial in Canada; (h) how many clinical trials have been initiated in Canada annually since 2010; (i) what cancer prevention programs, by cancer type, are funded by the government; (j) how much has the government invested since 2010 in the top 10 cancers, broken down by (i) cancer diagnosis, (ii) treatment, (iii) research, (iv) prevention, (v) federal transfers, and the specific amount, (vi) direct investment in cancer programs, and the specific amount, (vii) research funding, and how does the total investment compare to the United States; (k) how much has the government annually invested since 2010 in pediatric cancer, broken down by (i) diagnosis, (ii) treatment, (iii) research, (iv) prevention, (v) federal transfers, and the specific amount, (vi) direct investment in cancer programs, and the specific amount, (vii) research funding, and how does the total investment compare to the United States; (l) how much has the government invested since 2010 in rare cancer, broken down by (i) diagnosis, (ii) treatment, (iii) research, (iv) prevention, (v) federal transfers, and the specific amount, (vi) direct investment in cancer programs, and the specific amount, (vii) research funding, and how does the total investment compare to the United States; (m) does the Scientific Advisory Committee on Oncology Therapies still exist, and, if so, (i) what is its membership, (ii) when did it last meet, (iii) what was on the agenda of all meetings since 2019; (n) what is the average approval time for phased clinical trials for the top 10 cancers in Canada, broken down by (i) phase I clinical trials, (ii) phase II clinical trials, (iii) phase III clinical trials, (iv) phase IV clinical trials, and how do the approval times in (i), (ii), (iii) and (iv) compare to the United States; (o) what percentage of Canadian children undergoing cancer treatment have access to a clinical trial; (p) what is the average approval time for phased clinical trials for rare cancers in Canada, broken down by (i) phase I clinical trials, (ii) phase II clinical trials, (iii) phase III clinical trials, (iv) phase IV clinical trials, and how do the approval times in (i), (ii), (iii) and (iv) compare to the United States; (q) how many new cancer treatments has Health Canada (HC) approved since 2010 and what percentage have been precision treatments; (r) what are all cancer drugs approved in Canada, and the dates of approval since 2010, broken down by the (i) date the drug was approved in the United States, (ii) provinces and territories where the drug is available, (iii) provinces and territories covering the entire drug cost, (iv) provinces and territories requiring patient payment, (v) additional cost per treatment; (s) how many new cancer treatments has HC approved since 2010 for the top 10 cancers, what percentage have been precision treatments and how do the approval rates and times compare to those in the United States; (t) how many new pediatric cancer treatments has HC approved since 2010 and what percentage have been precision treatments; (u) how many new rare cancer treatments has HC approved since 2010 and what percentage have been precision treatments; (v) on what date was the special access program for drugs first put in place, (i) how many applications have been made for chemotherapy drugs since its creation, (ii) how many times have approvals been made for chemotherapy drugs since its creation, (iii) what is the average approval wait time for a chemotherapy drug, (iv) is there a process for re-application, and, if so, what is the average approval time for re-application of a chemotherapy drug; (w) what are the top 10 pediatric cancers since 2010 annually, broken down by province and territory, and, for each cancer, what is the (i) morbidity rate, (ii) mortality rate, (iii) five-year survival rate by stage, (iv) cost to the healthcare system; (x) for each rate in (w)(i) and (ii), what is the number of people affected; (y) what is the list of all rare cancers in Canada, how many people are affected by rare cancers, and what investments has the government made in their research; (z) what is the process for a clinician to access off-label chemotherapy options for a patient with a rare cancer, including (i) the average approval time, (ii) the re-approval process, and, if any, the average re-approval wait time, (iii) the approval success rate for application, (iv) if relevant, the approval success rate for re-application, (v) the approval success rate when a drug is already approved for use in another country; (aa) what is the average time to diagnosis for each of the (i) top 10 cancers, (ii) pediatric cancers, (iii) rare cancers, and what is the average cancer stage at diagnosis and the cost to the healthcare system, since 2010, broken down by province and territory; (bb) what was the average time to diagnosis for each of the (i) top 10 cancers, (ii) pediatric cancers, (iii) rare cancers, and what is the average cancer stage at diagnosis and the cost to the healthcare system, broken down by province and territory, and annually from 2019 to 2023; (cc) how many people had to seek diagnosis outside of Canada due to either wait time or lack of diagnostic technology or procedure, and what was the cost to the healthcare system, broken down by province and territory annually since 2010; (dd) how many people had to seek treatment outside of Canada due to either wait time or lack of treatment that was available elsewhere, and what was the cost to the healthcare system, broken down by province and territory annually since 2010; (ee) how many people could not get a recommended chemotherapy because (i) they did not have health insurance, (ii) their health coverage did not cover a chemotherapy drug, (iii) their insurance covered only part of the drug cost, broken down by province and territory; (ff) broken down by province and territory, how many times has the federal special access program been accessed since its inception, (i) how many approvals have been made since its inception, (ii) what is the average approval time, (iii) is there a process for re-application, and, if so, what is the average approval time for re-application; (gg) what has each government invested in cancer treatment since 2010, broken down by province and territory; and (hh) how much has the Canadian Institutes of Health Research invested annually in cancer research since 2010, and specifically what has been invested in (i) the top 10 cancers, (ii) pediatric cancers, (iii) rare cancers, and how does this annual total investment compare to the United States? — Sessional Paper No. 8555-441-2545.
|
| Government Orders |
|
The order was read for the second reading and reference to the Standing Committee on Public Safety and National Security of Bill C-70, An Act respecting countering foreign interference. |
Notice of the royal recommendation was given on Monday, May 6, 2024, by the Minister of Public Safety, Democratic Institutions and Intergovernmental Affairs as follows:
|
|
Recommendation |
|
(Pursuant to Standing Order 79(2)) |
Her Excellency the Governor General recommends to the House of Commons the appropriation of public revenue under the circumstances, in the manner and for the purposes set out in a measure entitled "An Act respecting countering foreign interference".
|
|
Mr. LeBlanc (Minister of Public Safety, Democratic Institutions and Intergovernmental Affairs), seconded by Mr. Rodriguez (Minister of Transport), moved, — That the bill be now read a second time and referred to the Standing Committee on Public Safety and National Security. |
|
Debate arose thereon. |
| Requests for Extension of Sitting Hours |
|
Pursuant to order made Wednesday, February 28, 2024, Mr. MacKinnon (Leader of the Government in the House of Commons) requested that the ordinary hour of daily adjournment on Thursday, May 30, 2024, be 12:00 a.m. and this request was deemed adopted. |
| Government Orders |
|
The House resumed consideration of the motion of Mr. LeBlanc (Minister of Public Safety, Democratic Institutions and Intergovernmental Affairs), seconded by Mr. Rodriguez (Minister of Transport), — That Bill C-70, An Act respecting countering foreign interference, be now read a second time and referred to the Standing Committee on Public Safety and National Security. |
|
The debate continued. |
| Motions |
|
By unanimous consent, it was ordered, — That, notwithstanding any standing order, special order or usual practice of the House, Bill C-70, An Act respecting countering foreign interference, be deemed read a second time and referred to the Standing Committee on Public Safety and National Security. |
| Government Orders |
|
The House resumed consideration of the motion of Mr. LeBlanc (Minister of Public Safety, Democratic Institutions and Intergovernmental Affairs), seconded by Mr. Rodriguez (Minister of Transport), — That Bill C-70, An Act respecting countering foreign interference, be now read a second time and referred to the Standing Committee on Public Safety and National Security. |
|
The debate continued. |
|
Pursuant to order made earlier today, the bill was deemed read a second time and referred to the Standing Committee on Public Safety and National Security. |
| Private Members' Business |
|
At 6:20 p.m., pursuant to Standing Order 30(7), the House proceeded to the consideration of Private Members' Business. |
|
The House resumed consideration of the motion of Ms. Lantsman (Thornhill), seconded by Mr. Majumdar (Calgary Heritage), — That Bill C-353, An Act to provide for the imposition of restrictive measures against foreign hostage takers and those who practice arbitrary detention in state-to-state relations and to make related amendments to the Proceeds of Crime (Money Laundering) and Terrorist Financing Act and the Immigration and Refugee Protection Act, be now read a second time and referred to the Standing Committee on Foreign Affairs and International Development. |
|
The debate continued. |
|
The question was put on the motion and, pursuant to Standing Order 93(1), the recorded division was deferred until Wednesday, June 5, 2024, at the expiry of the time provided for Oral Questions. |
| Returns and Reports Deposited with the Clerk of the House |
|
Pursuant to Standing Order 32(1), papers deposited with the Clerk of the House were laid before the House as follows: |
|
— by Mr. Blair (Minister of National Defence) — Report of the Chief of Defence Staff on the National Sex Offender Registry for the fiscal year ended March 31, 2024, pursuant to the National Defence Act, R.S., 1985, c. N-5, s. 227.171. — Sessional Paper No. 8560-441-1051-03. (Pursuant to Standing Order 32(5), permanently referred to the Standing Committee on National Defence) |
|
— by Mr. Fraser (Minister of Housing, Infrastructure and Communities) — Annual Report of the Federal Housing Advocate for the fiscal year ended March 31, 2024, pursuant to the National Housing Strategy Act, S.C. 2019, c. 29, s. 313 "16(2)". — Sessional Paper No. 8560-441-1290-03. (Pursuant to Standing Order 32(5), permanently referred to the Standing Committee on Human Resources, Skills and Social Development and the Status of Persons with Disabilities) |
| Adjournment Proceedings |
|
At 7:21 p.m., pursuant to Standing Order 38(1), the question “That this House do now adjourn” was deemed to have been proposed. |
|
After debate, pursuant to Standing Order 81(4)(a), the question was deemed to have been withdrawn. |
| Government Orders |
Business of Supply |
|
At 7:51 p.m., pursuant to Standing Order 81(4)(a), the House resolved itself into a committee of the whole for the consideration of all votes under Department of Health in the Main Estimates for the fiscal year ending March 31, 2025. |
| Midnight |
|
At 12:07 a.m., pursuant to order made earlier today, the committee rose. |
|
Pursuant to Standing Order 81(4)(a), the considered votes were deemed reported. |
| Adjournment |
|
Accordingly, at 12:07 a.m., the Speaker adjourned the House until later today at 10:00 a.m., pursuant to Standing Order 24(1). |